Favoured genetic background for testing anxiolytics in the fear-potentiated and light-enhanced startle paradigms in the rat

Behavioural Brain Research

Volumn 221, Issue 1, 2011, Pages 34-42

  Steiner, Michel A ^a   Lecourt, Hugues ^a   Rakotoariniaina, Ando ^a   Jenck, Francois ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Alprazolam; Anxiety; F344; Fear potentiated startle; Light enhanced startle; Rat strain

Indexed keywords

ALPRAZOLAM;

ANIMAL EXPERIMENT; ANIMAL GENETICS; ANXIETY; ARTICLE; CONDITIONING; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; FEAR POTENTIATED STARTLE; FISCHER 344 RAT; LIGHT ENHANCED STARTLE; LONG EVANS RAT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SPRAGUE DAWLEY RAT; STARTLE REFLEX; STRAIN DIFFERENCE; TRANQUILIZING ACTIVITY; WISTAR RAT;

ALPRAZOLAM; ANIMALS; ANTI-ANXIETY AGENTS; CONDITIONING, CLASSICAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEAR; HAND STRENGTH; MALE; PHOTIC STIMULATION; RATS; RATS, INBRED F344; RATS, LONG-EVANS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SPECIES SPECIFICITY; STARTLE REACTION;

EID: 79952708417     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.02.021     Document Type: Article

References (27)

1. Brown J.S., Kalish H.I., Farber I.E. Conditioned fear as revealed by magnitude of startle response to an auditory stimulus. J Exp Psychol 1951, 41:317-328.
2. Davis M. Pharmacological and anatomical analysis of fear conditioning using the fear-potentiated startle paradigm. Behav Neurosci 1986, 100:814-824.
3. Davis M. Pharmacological analysis of fear-potentiated startle. Braz J Med Biol Res 1993, 26:235-260.
4. Davis M. Are different parts of the extended amygdala involved in fear versus anxiety?. Biol Psychiatry 1998, 44:1239-1247.
5. Davis M. Neural systems involved in fear and anxiety measured with fear-potentiated startle. Am Psychol 2006, 61:741-756.
6. de Jongh R., Groenink L., van Der Gugten J., Olivier B. The light-enhanced startle paradigm as a putative animal model for anxiety: effects of chlordiazepoxide, flesinoxan and fluvoxamine. Psychopharmacology (Berl) 2002, 159:176-180.
7. de Jongh R., Groenink L., van der Gugten J., Olivier B. Light-enhanced and fear-potentiated startle: temporal characteristics and effects of alpha-helical corticotropin-releasing hormone. Biol Psychiatry 2003, 54:1041-1048.
8. Fendt M., Fanselow M.S. The neuroanatomical and neurochemical basis of conditioned fear. Neurosci Biobehav Rev 1999, 23:743-760.
9. Glowa J.R., Geyer M.A., Gold P.W., Sternberg E.M. Differential startle amplitude and corticosterone response in rats. Neuroendocrinology 1992, 56:719-723.
10. Glowa J.R., Hansen C.T. Differences in response to an acoustic startle stimulus among forty-six rat strains. Behav Genet 1994, 24:79-84.
11. Grillon C. Models and mechanisms of anxiety: evidence from startle studies. Psychopharmacology (Berl) 2008, 199:421-437.
12. Grillon C., Baas J. A review of the modulation of the startle reflex by affective states and its application in psychiatry. Clin Neurophysiol 2003, 114:1557-1579.
13. Grillon C., Baas J.M. Comments on the use of the startle reflex in psychopharmacological challenges: impact of baseline startle on measurement of fear-potentiated startle. Psychopharmacology (Berl) 2002, 164:236-238.
14. Grillon C., Pellowski M., Merikangas K.R., Davis M. Darkness facilitates the acoustic startle reflex in humans. Biol Psychiatry 1997, 42:453-460.
15. Groves P.M., Thompson R.F. Habituation: a dual-process theory. Psychol Rev 1970, 77:419-450.
16. Joordens R.J., Hijzen T.H., Peeters B.W., Olivier B. Fear-potentiated startle response is remarkably similar in two laboratories. Psychopharmacology (Berl) 1996, 126:104-109.
17. Koch M., Schnitzler H.U. The acoustic startle response in rats-circuits mediating evocation, inhibition and potentiation. Behav Brain Res 1997, 89:35-49.
18. Meloni E.G., Davis M. The dorsal cochlear nucleus contributes to a high intensity component of the acoustic startle reflex in rats. Hear Res 1998, 119:69-80.
19. Missig G., Ayers L.W., Schulkin J., Rosen J.B. Oxytocin reduces background anxiety in a fear-potentiated startle paradigm. Neuropsychopharmacology 2010, 35:2607-2616.
20. Muhlberger A., Wieser M.J., Pauli P. Darkness-enhanced startle responses in ecologically valid environments: a virtual tunnel driving experiment. Biol Psychol 2008, 77:47-52.
21. Pilz P.K., Linke R., Yilmazer-Hanke D.M., Schwegler H. Comparison of two sensitization paradigms of the acoustic startle response in Wistar and Sprague-Dawley rats. Behav Genet 1999, 29:59-63.
22. Rodriguez-Fornells A., Riba J., Gironell A., Kulisevsky J., Barbanoj M.J. Effects of alprazolam on the acoustic startle response in humans. Psychopharmacology (Berl) 1999, 143:280-285.
23. Walker D., Yang Y., Ratti E., Corsi M., Trist D., Davis M. Differential effects of the CRF-R1 antagonist GSK876008 on fear-potentiated, light- and CRF-enhanced startle suggest preferential involvement in sustained vs phasic threat responses. Neuropsychopharmacology 2009, 34:1533-1542.
24. Walker D.L., Davis M. Anxiogenic effects of high illumination levels assessed with the acoustic startle response in rats. Biol Psychiatry 1997, 42:461-471.
25. Walker D.L., Davis M. Double dissociation between the involvement of the bed nucleus of the stria terminalis and the central nucleus of the amygdala in startle increases produced by conditioned versus unconditioned fear. J Neurosci 1997, 17:9375-9383.
26. Walker D.L., Davis M. Quantifying fear potentiated startle using absolute versus proportional increase scoring methods: implications for the neurocircuitry of fear and anxiety. Psychopharmacology (Berl) 2002, 164:318-328.
27. Webb A.A., Gowribai K., Muir G.D. Fischer (F-344) rats have different morphology, sensorimotor and locomotor abilities compared to Lewis, Long-Evans, Sprague-Dawley and Wistar rats. Behav Brain Res 2003, 144:143-156.